Off-market insider buying at Spectral Medical (EDT)

Off-market insider buying at Spectral Medical (T:EDT)

Anthony Phillip Bihl, a Director, acquired 423,530 Common Shares on a direct ownership basis at a price of $0.425 through a prospectus or prospectus exempt offering on July 27th, 2021. The insider also acquired 211,765 Warrants on a direct ownership basis with an exercise price of $0.500 for 36 months. This represents a $180,000 investment into the company's shares and an account share holdings change of 73.7%.

Two other insiders also reported participating in smaller amounts. 

Spectral Medical is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Spectral Medical Inc. is a late stage theranostic company advancing therapeutic options for sepsis and septic shock. The Company has developed a product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA). The EAA is a rapid in-vitro diagnostic test that measures negative bacterial cell wall (endotoxin) activity in a whole blood sample. The Company, through its wholly owned subsidiary, Dialco Medical Inc. (Dialco), is also commercializing a new platform, SAMI. Its platform is targeting the renal replacement therapy (RRT) market.